Background: Warfarin has been the only anticoagulant used for decades to prevent strokes
and systemic embolisms in nonvalvular atrial fibrillation (NVAF) patients. Compared with …

Introduction Due to fixed dosing of direct oral anticoagulants (DOACs), uncertainty exists
about their efficacy in a population of obese/overweight patients. Patients and methods We …

Background: Low-dose prescription of rivaroxaban was common among patients with atrial
fibrillation (AF) in Asia. However, the benefits and harms of rivaroxaban at a low dosage in …

Background Rivaroxaban is a novel oral anticoagulant (NOAC) that is commonly used for
stroke prevention among patients with atrial fibrillation (AF). However, its cost effectiveness …

Background Rivaroxaban is a direct oral anticoagulant (DOAC) approved for the treatment of
non-valvular atrial fibrillation (NVAF). Data related to the risk factors associated with …

Aims Heart failure (HF) is a common co‐morbidity in non‐valvular atrial fibrillation (NVAF)
patients and a potent risk factor for stroke, bleeding, and a decreased time‐in‐therapeutic …

Background: The International Society of Thrombosis and Haemostasis recommends
avoiding direct oral anticoagulants (DOACs) in morbidly obese patients with a body mass …

Background: Warfarin has been the mainstay treatment used by patients with a moderate-to-
high risk of stroke due to non-valvular atrial fibrillation (NVAF). Unlike rivaroxaban …

Introduction The healthcare resource utilization (HRU) and costs of oral anticoagulant-naïve
patients with non-valvular atrial fibrillation (NVAF) and diabetes initiated on rivaroxaban or …

The approved dose of oral anticoagulant rivaroxaban for patients with non-valvular atrial
fibrillation (NVAF) in Japan is 15 mg once daily (od) in patients whose creatinine clearance …